Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines

Cancer Research

Volumn 56, Issue 1, 1996, Pages 206-209

  Tsai, Chun Ming ^a,b   Chang, Kuo Ting ^b   Wu, Li Hua ^b   Chen, Jeou Yuan ^a   Gazdar, Adi F ^c   Mitsudomi, Tetsuya ^d   Chen, Mei Hui ^b   Perng, Reury Perng ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN; MELPHALAN; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; ONCOGENE NEU; PRIORITY JOURNAL; TUMOR GROWTH;

CARCINOMA, NON-SMALL-CELL LUNG; CELL DIVISION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030031576     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Coussens, L., Yang-Feng, T. L , Liao, Y. C., Chen, E., Gray, A , McGrath, J , Seeburg, P. H , Libermann, T , Schlessinger, J., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science (Wash. DC), 230: 1132-1139, 1985.
2. Schneider, P. M., Hung, M. C., Chiocca, S. M., Manning, J., Zhao, X., Fang, K., and Roth, J. A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer Cancer Res , 49: 4968-4971, 1989.
3. neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res., 50: 5184-5191, 1990.
4. Tsai, C. M , Chang, K T., Perng, R P., Mitsudomi, T., Chen, M. H., Kadoyama, C., Gazdar, A. F Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst., 85: 897-901, 1993
5. neu in the HER-2/neu-transfected human lung cancer cells. J Natl. Cancer Inst., 87: 682-684, 1995.
6. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents Cell, 74: 957-967, 1993.
7. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164-4168, 1993.
8. Fujiwara, T., Grimm, E A., Mukhopadhyay, T , Zhang, W. W , Owen-Schaub, L. B , and Roth, J. A Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2291, 1994.
9. Kallioniemi, O P., Holli, K., Visakorpi, T., Koivula, T., Helin, H H., and Isola, J. J. Association of c-erbB-2 protein over-expression with high rale of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int. J. Cancer, 49 650-655, 1991
10. Merlo, G R., Bernardi, A., Diella, F., Venesio, T., Cappa, A. P. M , Callahan, R., and Liscia, D. S. In primary human breast carcinomas mutations in exons 5 and 6 of the p53 gene are associated with a high S-phase index. Int. J. Cancer, 54: 531-535, 1993
11. Allred, D C., Clark, G. M., Elledge, R , Fuqua, S. A. W., Brown, R. W., Chamness, G C , Osborne, C. K., and McGuire, W L. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst., 85: 200-206, 1993
12. Gusterson, B. A., Gelber, R. D., Goldhirsch, A , Price, K. N., Save-Söderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C-M., Golouh, R., Reed, R. Martinez-Tello, F., Tiltman, A., Torhorst, J , Grigolato, P., Bettelheim, R , Neville, A. M., Burki, K , Castiglione, M., Collins, J., Lindtner, J , and Senn, H-J. for the International (Ludwig) Breast Cancer Study Group Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin Oncol , 10. 1049-1056, 1992.
13. Wright, C., Cairns, J., Cantwell, B. J , Cattan, A R., Hall, A. G , Harris, A L , and Horne, C H. W. Response to mitoxanthrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br J. Cancer, 65. 271-274, 1992.
14. Barnes, D. M , Bartkova, J., Camplejohn, R. S., Gullick, W. J., Smith, P. J , and Millis, R. R. Overexpression of the c-erbB-2 oncoprotein, why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this prognostic significance? Eur. J. Cancer, 28: 644-648, 1992.
15. Muss, H. B., Thor, A D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. N. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
16. Koechli, O., Schaer, G. N., Seifert, B., Hornung, R., Haller, U., Eppenberger, U., and Mueller, H. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet, 344. 1647-1648, 1994.
17. Petty, R D., Cree, I. A., Sutherland, L. A., Hunter, E. M., Lane, D P., Preece, P. E., and Andreotti, P. E. Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity. Biochem. Biophys Res. Commun., 199. 264-270, 1994
18. neu expressing human non-small cell lung cancer cell lines. J. Natl Cancer Inst., 86: 1018-1020, 1994.
19. Chiu, J. H., Kao, H L., Wu, L H., Chang, H. M., and Lui, W. Y. Prediction of relapse or survival after resection in human hepatomas by DNA flow cytometry. J. Clin Invest., 89: 539-545, 1992.
20. Mitsudomi, T., Steinberg, S. M , Nau, M M., Carbone, D , D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I , Mulshine, J. L., Minna, J D , and Gazdar, A. F. p53 gene mutations in non-small cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features Oncogene, 7: 171-180, 1992.
21. Tannock, I. F. Biological properties of anticancer drugs. In: I. F. Tannock and R. P. Hill (eds.), The Basic Science of Oncology, pp. 278-291 New York: Pergamon Press, Inc , 1987
22. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 2018-2023, 1993
23. Quinlan, D. C., Davidson, A G , Summers, C. L., Warden, H. E , and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992
24. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Relationship of p53 Overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res , 54. 2496-2503, 1994.
25. Plowman, G. D., Culouscou, J M., Whitney, G. S., Green, J. M , Carlton, G. W., Foy, L., Neubauer, M. G , and Shoyab, M. Ligand-specific activation of HER4/p185erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA, 90: 1746-1750, 1993.
26. Kwok, T. T., and Sutherland, R. M Enhancement of sensitivity of human squamous carcinoma cells to radiation by epidermal growth factor. J. Natl. Cancer Inst., 81: 1020-1024, 1989
27. Christen, R. D , Hom, D. K., Porter, D. C., Andrews, P. A., MacLeod, C. L., Hafstrom, L , and Howell, S. B. Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J. Clin. Invest , 86: 1632-1640, 1990
28. Schlegel, R., and Pardee, A Caffeine induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science (Wash DC), 232: 1264-1266, 1986
29. Fingert, H. J., Chang, J D., and Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res., 46. 2463-2467, 1986.
30. Pietras, R. J., Fendly, B. M., Chazin, V R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994
31. Arteaga, C. L., Winnier, A. R., Poirier, M. C , Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D., and Stewart, S J. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells, association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair Cancer Res., 54: 3758-3765, 1994.